48,466
edits
Difference between revisions of "Renal neoplasms with TSC/mTOR pathway mutations"
Jump to navigation
Jump to search
Renal neoplasms with TSC/mTOR pathway mutations (view source)
Revision as of 04:28, 20 March 2024
, 20 Marchno edit summary
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]]. | '''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].<ref>{{cite journal |authors=Kapur P, Brugarolas J, Trpkov K |title=Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting |journal=Cancers (Basel) |volume=15 |issue=16 |pages= |date=August 2023 |pmid=37627070 |pmc=10452688 |doi=10.3390/cancers15164043 |url=}}</ref> | ||
Kidney tumours with TSC/mTOR mutations: | Kidney tumours with TSC/mTOR mutations: | ||
| Line 7: | Line 7: | ||
*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | *[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | ||
Mnemonic: ''REEL''. | |||
==See also== | |||
*[[Everolimus]]. | |||
==References== | ==References== | ||